Clinical Trials
15
7 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
2014
Active, not recruiting
3
20.0%
Completed
2
13.3%
Not yet recruiting
4
26.7%
Recruiting
4
26.7%
Terminated
1
6.7%
Unknown
1
6.7%
No approval data available
- Australian researchers identified low miR-342 levels and high E2F pathway activity as drivers of metastasis in triple-negative breast cancer (TNBC), published in EMBO Molecular Medicine. - In pre-clinical models, restoring miR-342 markedly reduced cancer spread to organs including the lungs and bones. - The existing CDK4/6 inhibitor palbociclib significantly reduced metastatic tumor growth in models with low miR-342, suggesting a repurposing opportunity. - Measuring miR-342 could identify a TNBC subgroup most likely to benefit from CDK4/6 inhibitors, with patient-derived models planned before clinical trials.
- Ribociclib (Kisqali) is now subsidized on Australia's Pharmaceutical Benefits Scheme for early-stage breast cancer patients with hormone receptor-positive, HER2-negative disease at high risk of recurrence. - The NATALEE trial demonstrated that adding ribociclib to standard hormone therapy reduced cancer recurrence risk by 28.5% compared to hormone therapy alone in 5,101 patients. - The PBS listing saves patients over $140,000 in treatment costs, as the drug previously cost approximately $3,700-$4,000 per month for three years without subsidy. - This development provides treatment options for approximately 70% of early-stage breast cancer cases, representing the most common subtype of the disease.
